Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting (abst – 1981)http://www.ncbi.nlm.nih.gov/pubmed/7298877
Randomised Clinical Trial of Levonantradol and Chlorpromazine in the Prevention of Radiotherapy-induced Vomiting (abst - 1982)http://www.ncbi.nlm.nih.gov/pubmed/6754212
Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy (abst – 1982) http://www.ncbi.nlm.nih.gov/pubmed/7139853
Respiratory and cardiovascular depressant effects of nabilone, N-methyllevonantradol and delta 9-tetrahydrocannabinol in anesthetized cats (abst – 1983) http://jpet.aspetjournals.org/conten...urcetype=HWCIT
Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy (abst – 1983) http://www.ncbi.nlm.nih.gov/pubmed/6309451
Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting (abst – 1985)http://www.ncbi.nlm.nih.gov/pubmed/2981616
Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses (abst – 1999)http://www.ncbi.nlm.nih.gov/pubmed/10080239
Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor (full – 2000)http://onlinelibrary.wiley.com/doi/1...0750413.x/full
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A (full – 2001) http://www.nature.com/npp/journal/v2.../1395605a.html
Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse? (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/arti...1/?tool=pubmed
Transdermal delivery of cannabidiol Patent 8435556 (full – 2013) https://www.google.com/patents/US8435556
Levonantradol: asymmetric synthesis and structural analysis (abst – 2013) http://pubs.rsc.org/en/Content/Artic.../CC/c3cc41388h
Randomised Clinical Trial of Levonantradol and Chlorpromazine in the Prevention of Radiotherapy-induced Vomiting (abst - 1982)http://www.ncbi.nlm.nih.gov/pubmed/6754212
Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy (abst – 1982) http://www.ncbi.nlm.nih.gov/pubmed/7139853
Respiratory and cardiovascular depressant effects of nabilone, N-methyllevonantradol and delta 9-tetrahydrocannabinol in anesthetized cats (abst – 1983) http://jpet.aspetjournals.org/conten...urcetype=HWCIT
Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy (abst – 1983) http://www.ncbi.nlm.nih.gov/pubmed/6309451
Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting (abst – 1985)http://www.ncbi.nlm.nih.gov/pubmed/2981616
Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses (abst – 1999)http://www.ncbi.nlm.nih.gov/pubmed/10080239
Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor (full – 2000)http://onlinelibrary.wiley.com/doi/1...0750413.x/full
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A (full – 2001) http://www.nature.com/npp/journal/v2.../1395605a.html
Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse? (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/arti...1/?tool=pubmed
Transdermal delivery of cannabidiol Patent 8435556 (full – 2013) https://www.google.com/patents/US8435556
Levonantradol: asymmetric synthesis and structural analysis (abst – 2013) http://pubs.rsc.org/en/Content/Artic.../CC/c3cc41388h